Contact us Demo our platform

METABOLON @

EpiLipidNet Action Meeting 2024

  • Dresden, Germany
  • May 13 - May 15, 2024

Metabolon is thrilled to sponsor the 5th EpiLipidNet Meeting in Dresden, Germany from the 13th to 15th of May. EpiLipidNET aims to build and maintain a multidisciplinary pan-European network of researchers, clinicians and enterprises working in the field of lipidomics and epilipidomics.

The meeting will feature 7 scientific sessions with oral presentations, 2 dedicated poster sessions, and several social events to support networking and knowledge exchange. Metabolon is pleased to present a poster on the ‘Development and Analytical Validation of a Sphingolipid Targeted Panel.’

For more event information, you can read visit the official event website or read the official program.

Join us at the sponsorship tables

Come meet our team at the sponsorship tables to learn how Metabolon is advancing metabolomic and lipidomic research. Schedule a meeting here to guarantee 1:1 time with a metabolomics expert.

Event Location

CRTD Zentrum für Regenerative Therapien TU Dresden
Fetscherstraße 105,
01307 Dresden,
Germany
Google Maps

Why Metabolomics: Your Guide to Metabolomics

In this guide, we explore the ins and outs of one of the most powerful omics tools in any scientist’s toolbox, one that can complement any existing workflow and help realize the full potential of other omics methods: metabolomics.

Read now

Schedule a Meeting

Meet the Reps Attending EpiLipidNet 2024

Zoltan Bognar

Zoltan Bognar

Business Development Executive

Zoltan has over 25 years of experience providing researchers with services and products in various research fields in life sciences. He possesses strong skills in providing research-related services and offers both our preclinical and clinical analysis solutions to academic and industrial clients. Based in Berlin, he serves as your contact person in the DACH region.

Alessandro Busetti, Ph.D.

Alessandro Busetti, Ph.D.

Field Metabolomics Scientist

Dr Busetti is one of Metabolon’s most experienced Field Metabolomics Scientists and supports client projects across Europe and Asia. Alessandro obtained his bachelor’s degree in biology and his master’s degree in molecular biology at the University of Rome, La Sapienza. He obtained his PhD in pharmaceutical microbiology at The Queen’s University, Belfast (QUB).

Dr. Busetti spent 10 years conducting research in academia, both as a Research Fellow at QUB and as a Research Associate at the University of Glasgow. His research focused on the discovery of marine-derived bioactives for biomedical applications and understanding the role of microbiomes in regulating host health.

In 2016 he transitioned into the industry and joined 4D Pharma PLC where he worked as the Senior Team Leader of the “Discovery-Micro” Department. There, he defined and implemented screening strategies to identify candidate LBP strains for a number of disease areas ranging from autoimmune diseases, solid tumors, neurodegenerative diseases, and more.

Dr. Busetti is a true scientific chameleon with a broad knowledge of many research areas of focus, but his main passion remains host-microbe interactions, microbiome studies, and “sociomicrobiology.” He is based in Verona, Italy, where he lives with his wife and daughter.

✕

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.